• BillionToOne disclosed peer-reviewed study results on June 29, 2026; findings were already published, not flagged for a future presentation.
• Northstar Response blood-based monitoring predicted immunotherapy outcomes more reliably than standard imaging across advanced solid tumors.
• Combining molecular monitoring with imaging sharpened risk stratification, helping flag likely non-responders even when scans read as stable disease.
• Serial testing detected progression earlier than clinicoradiographic assessment, creating a potential window to adjust surveillance or treatment strategy sooner.
• Results were reproduced in a separate prospective validation cohort, supporting broader clinical adoption for immunotherapy monitoring.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Billiontoone Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA94395) on June 29, 2026, and is solely responsible for the information contained therein.